Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Validity of the Turkish Situational Vertigo Questionnaire

NCT07468864 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-02-16
Last updated
2026-03-13

Condition(s) studied

Vestibular Pathology

Investigational drug(s) / intervention(s)

validity and reliability

validity and reliability: The Turkish adaptation of the Situational Vertigo Questionnaire (SVQ) will follow internationally accepted cross-cultural adaptation guidelines using a forward-backward translation method. Two independent bilingual translators will translate the original English version into Turkish, producing two versions that will be compared and synthesized into a preliminary Turkish form. This version will then be back-translated into English by two native English speakers blinded to the original scale. A committee of translators and experts will review all versions to ensure conceptual and linguistic equivalence and create a pre-final Turkish version. The pre-final version will be pilot tested with 20 participants to assess clarity and comprehension. Items reported as unclear will be revised. Finally, the scale will be administered to a larger sample for psychometric evaluation of validity and reliability.

Study summary

This study was planned to examine the validity and reliability of the Turkish version of the Situational Vertigo Questionnaire (SVQ), which is used to evaluate dizziness symptoms frequently seen in vestibular pathologies and triggered by visual or environmental stimuli. The research is designed as a methodological scale adaptation and psychometric evaluation study. The study plans to include individuals aged 18 and over who can read and understand Turkish and have complaints of situational dizziness. The Turkish adaptation process of the SVQ will be carried out using the back-and-forth translation method; a pilot application will be conducted after ensuring linguistic and cultural equivalence. For the psychometric evaluation, the sample size is planned to be at least 10 times the number of items, and participants will be asked to complete the SVQ, as well as the Dizziness Handicap Inventory (DHI), Vertigo Symptom Scale (VSS), and Visual Analog Scale (VAS). To evaluate test-retest reliability, a subgroup of participants will be re-administered the SVQ after 7 days. No invasive procedures will be performed on participants during the research; only survey forms will be used. Written informed consent will be obtained from all participants, and data will be coded and analyzed in accordance with confidentiality principles. It is expected that the findings of this study will contribute to the literature by establishing a valid and reliable measurement tool in Turkish for the evaluation of situational dizziness symptoms and will support clinical evaluation processes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Presence of dizziness triggered by visual or environmental stimuli * Able to read and write Turkish * Voluntary agreement to participate in the study * Having the mental capacity to give informed consent (Mini Mental State Scale score ≥ 24) Exclusion Criteria: * Individuals with severe cognitive impairment or communication difficulties * Acute neurological disease (stroke, acute MS relapse, etc.) * Having undergone vestibular surgery within the last 3 months

Primary outcome measure(s)

  • Situational Vertigo Questionnaire (SVQ) — Baseline and 7-14 days follow-up
    The Situational Vertigo Questionnaire (SVQ) is a 19-item self-report scale designed to assess visual vertigo associated with increased visual dependence and insufficient vestibular compensation. Visual vertigo refers to dizziness triggered or worsened in visually complex or disorienting environments such as supermarkets, driving, or moving visual scenes. The condition is thought to arise from difficulties resolving conflicts between visual, vestibular, and proprioceptive inputs. The SVQ asks individuals to rate the severity of dizziness in situations involving visual motion or visual-vestibular conflict. Each item is scored from 0 (none) to 4 (severe), and participants may select "never experienced" if applicable. The total score is calculated based on the average item score, adjusted for items marked as not experienced, with higher scores indicating more severe symptoms.

Trial sites (1)

FacilityCityRegionStatus
Güneşli Erdem Hastanesi Bağcılar Güneşli Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07468864 on ClinicalTrials.gov ↗ ← All trials in Turkey